Péter Major1, István Baczkó2, László Hiripi1, Katja E Odening3, Viktor Juhász2, Zsófia Kohajda2, András Horváth2, György Seprényi4, Mária Kovács2, László Virág2, Norbert Jost2,5, János Prorok2, Balázs Ördög2, Zoltán Doleschall6, Stanley Nattel7,8,9, András Varró2,5, Zsuzsanna Bősze1. 1. Rabbit Genome and Biomodel Group, NARIC - Agricultural Biotechnology Institute, Gödöllő, Hungary. 2. Department of Pharmacology & Pharmacotherapy, University of Szeged, Szeged, Hungary. 3. Department of Cardiology and Angiology I, Heart Center University of Freiburg, Freiburg, Germany. 4. Department of Biology, University of Szeged, Szeged, Hungary. 5. MTA-SZTE Research Group of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary. 6. Department of Pathogenetics, National Institute of Oncology, Budapest, Hungary. 7. Department of Medicine, Montreal Heart Institute, Université de Montréal, Canada. 8. Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada. 9. Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND AND PURPOSE: The reliable assessment of proarrhythmic risk of compounds under development remains an elusive goal. Current safety guidelines focus on the effects of blocking the KCNH2/HERG ion channel-in tissues and animals with intact repolarization. Novel models with better predictive value are needed that more closely reflect the conditions in patients with cardiac remodelling and reduced repolarization reserve. EXPERIMENTAL APPROACH: We have developed a model for the long QT syndrome type-5 in rabbits (LQT5 ) with cardiac-specific overexpression of a mutant (G52R) KCNE1 β-subunit of the channel that carries the slow delayed-rectifier K(+) -current (IKs ). ECG parameters, including short-term variability of the QT interval (STVQT ), a biomarker for proarrhythmic risk, and arrhythmia development were recorded. In vivo, arrhythmia susceptibility was evaluated by i.v. administration of the IKr blocker dofetilide. K(+) currents were measured with the patch-clamp technique. KEY RESULTS: Patch-clamp studies in ventricular myocytes isolated from LQT5 rabbits revealed accelerated IKs and IKr deactivation kinetics. At baseline, LQT5 animals exhibited slightly but significantly prolonged heart-rate corrected QT index (QTi) and increased STVQT . Dofetilide provoked Torsade-de-Pointes arrhythmia in a greater proportion of LQT5 rabbits, paralleled by a further increase in STVQT . CONCLUSION AND IMPLICATIONS: We have created a novel transgenic LQT5 rabbit model with increased susceptibility to drug-induced arrhythmias that may represent a useful model for testing proarrhythmic potential and for investigations of the mechanisms underlying arrhythmias and sudden cardiac death due to repolarization disturbances.
BACKGROUND AND PURPOSE: The reliable assessment of proarrhythmic risk of compounds under development remains an elusive goal. Current safety guidelines focus on the effects of blocking the KCNH2/HERG ion channel-in tissues and animals with intact repolarization. Novel models with better predictive value are needed that more closely reflect the conditions in patients with cardiac remodelling and reduced repolarization reserve. EXPERIMENTAL APPROACH: We have developed a model for the long QT syndrome type-5 in rabbits (LQT5 ) with cardiac-specific overexpression of a mutant (G52R) KCNE1 β-subunit of the channel that carries the slow delayed-rectifier K(+) -current (IKs ). ECG parameters, including short-term variability of the QT interval (STVQT ), a biomarker for proarrhythmic risk, and arrhythmia development were recorded. In vivo, arrhythmia susceptibility was evaluated by i.v. administration of the IKr blocker dofetilide. K(+) currents were measured with the patch-clamp technique. KEY RESULTS: Patch-clamp studies in ventricular myocytes isolated from LQT5 rabbits revealed accelerated IKs and IKr deactivation kinetics. At baseline, LQT5 animals exhibited slightly but significantly prolonged heart-rate corrected QT index (QTi) and increased STVQT . Dofetilide provoked Torsade-de-Pointes arrhythmia in a greater proportion of LQT5 rabbits, paralleled by a further increase in STVQT . CONCLUSION AND IMPLICATIONS: We have created a novel transgenic LQT5 rabbit model with increased susceptibility to drug-induced arrhythmias that may represent a useful model for testing proarrhythmic potential and for investigations of the mechanisms underlying arrhythmias and sudden cardiac death due to repolarization disturbances.
Authors: V Duranthon; N Beaujean; M Brunner; K E Odening; A Navarrete Santos; I Kacskovics; L Hiripi; E J Weinstein; Z Bosze Journal: Transgenic Res Date: 2012-03-02 Impact factor: 2.788
Authors: Martin Hinterseer; Britt-Maria Beckmann; Morten B Thomsen; Arne Pfeufer; Michael Ulbrich; Moritz F Sinner; Siegfried Perz; H-Erich Wichmann; Csaba Lengyel; Rainer Schimpf; Sebastian K G Maier; András Varró; Marc A Vos; Gerhard Steinbeck; Stefan Kääb Journal: Am J Cardiol Date: 2010-07-15 Impact factor: 2.778
Authors: I Splawski; J Shen; K W Timothy; M H Lehmann; S Priori; J L Robinson; A J Moss; P J Schwartz; J A Towbin; G M Vincent; M T Keating Journal: Circulation Date: 2000-09-05 Impact factor: 29.690
Authors: Stephen Ph Alexander; William A Catterall; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Nipavan Chiamvimonvat; Ye Chen-Izu; Colleen E Clancy; Isabelle Deschenes; Dobromir Dobrev; Jordi Heijman; Leighton Izu; Zhilin Qu; Crystal M Ripplinger; Jamie I Vandenberg; James N Weiss; Gideon Koren; Tamas Banyasz; Eleonora Grandi; Michael C Sanguinetti; Donald M Bers; Jeanne M Nerbonne Journal: J Physiol Date: 2017-01-05 Impact factor: 5.182
Authors: Alessandro Castiglione; Tibor Hornyik; Eike M Wülfers; Lucilla Giammarino; Iask Edler; Jessica J Jowais; Marina Rieder; Stefanie Perez-Feliz; Gideon Koren; Zsuzsanna Bősze; András Varró; Manfred Zehender; Michael Brunner; Christoph Bode; Sara I Liin; Hans Peter Larsson; István Baczkó; Katja E Odening Journal: Europace Date: 2022-03-02 Impact factor: 5.486
Authors: Hany M El-Bassossy; Wafaa S Al-Thubiani; Ahmed A Elberry; Mohammad I Mujallid; Salah A Ghareib; Ahmad S Azhar; Zainy M Banjar; Malcolm L Watson Journal: PLoS One Date: 2017-12-05 Impact factor: 3.240
Authors: András Horváth; Marc D Lemoine; Alexandra Löser; Ingra Mannhardt; Frederik Flenner; Ahmet Umur Uzun; Christiane Neuber; Kaja Breckwoldt; Arne Hansen; Evaldas Girdauskas; Hermann Reichenspurner; Stephan Willems; Norbert Jost; Erich Wettwer; Thomas Eschenhagen; Torsten Christ Journal: Stem Cell Reports Date: 2018-02-08 Impact factor: 7.765
Authors: Tibor Hornyik; Alessandro Castiglione; Gerlind Franke; Stefanie Perez-Feliz; Péter Major; László Hiripi; Gideon Koren; Zsuzsanna Bősze; András Varró; Manfred Zehender; Michael Brunner; Christoph Bode; István Baczkó; Katja E Odening Journal: Br J Pharmacol Date: 2020-06-24 Impact factor: 8.739
Authors: Péter Ferdinandy; István Baczkó; Péter Bencsik; Zoltán Giricz; Anikó Görbe; Pál Pacher; Zoltán V Varga; András Varró; Rainer Schulz Journal: Eur Heart J Date: 2019-06-07 Impact factor: 29.983